JEFFREY SHIDEMAN: Open Payments
NPI 1699316430 · SHERIDAN, WY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$352 in 19 payments from 9 companies in 2025. Trend: 2023 $370 · 2024 $352 · 2025 $352
Food & beverage: $352
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $94 |
| Novo Nordisk Inc | 3 | $54 |
| Madrigal Pharmaceuticals | 2 | $53 |
| Amgen Inc. | 2 | $33 |
| Lilly USA, LLC | 2 | $29 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| GlaxoSmithKline, LLC. | 1 | $22 |
| Edwards Lifesciences Corporation | 1 | $20 |
Products named: BREZTRI, REZDIFFRA, MOUNJARO, CAPLYTA, Veozah, TRELEGY ELLIPTA, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), OTEZLA.
Industry payments across WY — which companies pay providers there.
